Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000876
English
Authors' recommendations:
Trastuzumab (Herceptin®) 150 mg powder for concentrate for solution for infusion is recommended as an option for use within NHS Wales for the treatment of HER2 positive early breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant trastuzumab therapy for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/trastuzumab%20%28Herceptin%29%20FAR1.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Stomach Neoplasms
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.